Patents by Inventor Melanie K. Tallent

Melanie K. Tallent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPLICE MODULATING OLIGONUCLEOTIDES TARGETING RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND METHODS OF USE
    Publication number: 20220265864
    Abstract: The invention provides splice modulating oligonucleotides (SMOs) designed to modulate the splicing of a RAGE pre-mRNA, compositions including the SMOs, and methods of treating and preventing diseases and conditions using the SMOs and compositions.
    Type: Application
    Filed: August 15, 2019
    Publication date: August 25, 2022
    Inventors: Nicole M. LYKENS, Gordon J. LUTZ, Melanie K. TALLENT
  • SPLICE MODULATING OLIGONUCLEOTIDES TARGETING RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS AND METHODS OF USE
    Publication number: 20210246454
    Abstract: The invention provides splice modulating oligonucleotides (SMOs) designed to modulate the splicing of a RAGE pre-mRNA, compositions including the SMOs, and methods of treating and preventing diseases and conditions using the SMOs and compositions.
    Type: Application
    Filed: May 17, 2019
    Publication date: August 12, 2021
    Inventors: Nicole M. LYKENS, Gordon J. LUTZ, Melanie K. TALLENT
  • Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
    Patent number: 10337015
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: July 2, 2019
    Assignee: Drexel University
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • MODULATION OF PRE-MRNA USING SPLICE MODULATING OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS IN THE TREATMENT OF DISEASE
    Publication number: 20180355361
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Application
    Filed: July 30, 2018
    Publication date: December 13, 2018
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
    Patent number: 10041075
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: August 7, 2018
    Assignee: Drexel University
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • MODULATION OF PRE-MRNA USING SPLICE MODULATING OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS IN THE TREATMENT OF DISEASE
    Publication number: 20180100156
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Application
    Filed: December 6, 2017
    Publication date: April 12, 2018
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • Modulation of pre-MRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
    Patent number: 9885049
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: February 6, 2018
    Assignee: Drexel University
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • MODULATION OF PRE-MRNA USING SPLICE MODULATING OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS IN THE TREATMENT OF DISEASE
    Publication number: 20170037411
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Application
    Filed: May 20, 2016
    Publication date: February 9, 2017
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
    Patent number: 9359603
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: June 7, 2016
    Assignee: Drexel University
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • MODULATION OF PRE-MRNA USING SPLICE MODULATING OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS IN THE TREATMENT OF DISEASE
    Publication number: 20140249210
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Application
    Filed: February 24, 2014
    Publication date: September 4, 2014
    Applicant: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • Modulation of pre-mRNA using splice modulating oligonucleotides as therapeutic agents in the treatment of disease
    Patent number: 8680254
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: March 25, 2014
    Assignee: Philadelphia Health & Education Corporation
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens
  • MODULATION OF pre-mRNA USING SPLICE MODULATING OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS IN THE TREATMENT OF DISEASE
    Publication number: 20120316223
    Abstract: The present invention encompasses a class of compounds known as splice modulating oligonucleotides (SMOs) that modulate pre-mRNA splicing, thereby affecting expression and functionality of a specific protein in a cell. The present invention further provides compositions and methods for modulating pre-mRNA splicing using a SMO of the invention to abrogate disease-causing mutations in a protein. Accordingly, the present invention provides compositions and methods of treating a subject at risk of, susceptible to, or having a disease, disorder, or condition associated with aberrant or unwanted target pre-mRNA expression or activity.
    Type: Application
    Filed: January 14, 2010
    Publication date: December 13, 2012
    Applicant: Philadelphia Health and Education Corp. d/b/a Drexel University College of Medicine
    Inventors: Gordon J. Lutz, Melanie K. Tallent, Nicole Michele Lykens